NEWARK, Calif., Dec. 5, 2018 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
Executive Officer, will provide a corporate overview at the BMO
Capital Markets 2018 Prescriptions for Success Healthcare
Conference in New York.
Presentation details:
Event:
|
BMO Capital Markets
2018 Prescriptions for Success Healthcare Conference
|
|
Date:
|
Wednesday, Dec. 12,
2018
|
|
Time:
|
9:20 a.m.
EST
|
|
A live and archived audio webcast of the presentation can be
accessed by visiting the Investors page of the Protagonist
Therapeutics website at http://investors.protagonist-inc.com.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to transform existing
treatment paradigms for patients with significant unmet medical
needs. PTG-200 is an oral peptide interleukin-23 receptor
antagonist in development for the treatment of Crohn's disease, and
it has completed Phase 1 studies in healthy volunteers. The company
has entered into a worldwide license and collaboration agreement
with Janssen Biotech for the clinical development of PTG-200.
PN-10943 is an oral, gut-restricted alpha-4-beta-7 integrin
antagonist peptide that is under development for treatment of
ulcerative colitis. Protagonist is also developing an injectable
hepcidin mimetic, PTG-300, for the potential treatment of anemia
and iron overload related to rare blood diseases with an initial
focus on beta thalassemia. A global Phase 2 trial in patients with
beta thalassemia will be initiated by the end of 2018.
Protagonist is headquartered in Newark, California, with pre-clinical and
clinical staff in California and
discovery operations in both California and Brisbane, Queensland, Australia. For further
information, please visit http://www.protagonist-inc.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-bmo-capital-markets-2018-prescriptions-for-success-healthcare-conference-300760052.html
SOURCE Protagonist Therapeutics, Inc.